Introduction
Ataxia-telangiectasia (A-T) is an autosomal recessive disorder with a pleiotropic phenotype involving neurodegeneration, telangiectasia, hypogonadism, growth retardation, immunodeficiency, cancer predisposition, chromosomal instability, and sensitivity to ionizing radiation (IR). 1, 2 The frequency of A-T in the United States has been estimated to be between 1:40 000 and 1:100 000, reflecting a carrier frequency of 0.5-1%. 3 No efffective treatments have been found to alter the course of this disease. The complexity of A-T is reflected in the cellular phenotype including reduced cell lifespan in culture, chromosomal instability, hypersensitivity to IR and radiomimetic agents, defective radiation-induced checkpoints at the G 1 , S and G 2 phases of the cell cycle, and defects in several signal transduction pathways. 4, 5 The responsible gene, ATM (ataxia-telangiectasia mutated), was cloned in 1995 and occupies 150 kb of genomic DNA coding for a 13 kb mRNA with an open reading frame of 9.165 kb. 6 ATM is a 370 kD protein with a carboxy-terminal domain homologous to the catalytic subunits of phosphatidylinositol 3-kinases (PI-3Ks). 6, 7 This family of large proteins sharing the PI-3K domain is involved in maintaining genome stability, cell cycle control, and cellular responses to damaging agents. 8 The cell cycle can potentially arrest at several stages, but following exposure to DNA-damaging agents, it usually does so before S phase or during S phase (known as the G 1 -and S-phase checkpoints, respectively) to prevent the cell from progressing through DNA replication, or before mitosis (the G 2 checkpoint) to prevent aberrant segregation of damaged chromosomes. 5 IR thus induces arrest in the G 1 , S, or G 2 phases of the mammalian cell cycle, and the ATM protein plays a role in initiating checkpoint pathways in all three of these cell cycle phases. 9, 10 Several targets of the ATM kinase have been identified that participate in these IR-induced cell cycle arrests. For example, phosphorylation of p53, Mdm2, and Chk2 participate in the G 1 checkpoint; [11] [12] [13] Nbs1, Brca1, SMC1, and FancD2 participate in the transient IR-induced S-phase arrest; [14] [15] [16] [17] and Brca1 and hRad17 have been implicated in the G2/M checkpoint. 18, 19 Previous research has shown that it is possible to correct A-T deficiencies by DNA transfection in cell culture, 20, 21 and that overexpression of the normal ATM protein does not cause cellular abnormalities. 22 The large size of the ATM cDNA (B9 kb) required to correct the hereditary deficiency in A-T limits use of many vectors for gene delivery. Basic HSV-1 amplicons are plasmidbased vectors that, in addition to the transgene of interest and a reporter gene, include two noncoding HSV-1 sequences, an origin of DNA replication (ori s ) and a DNA cleavage-packaging signal (pac), to allow packaging of concatenated amplicon DNA into HSV-1 virions in the presence of helper virus functions. 23, 24 HSV amplicon vectors have several features that make them well suited for delivery of the ATM cDNA: they are highly efficient at infecting neural, as well as many other cell types in culture and in animal models; 25, 26 they can bear large DNA fragments, up to 150 kb; 27 and they can be packaged without helper virus, thereby reducing their toxicity. 25, 28 In this study, we report the construction of the first viral vector, an HSV-1 amplicon, carrying the full-length ATM cDNA, and the use of this vector to correct aspects of the cellular phenotype of A-T cells. This vector provides a tool to evaluate biochemical and cellular responses to ATM replacement in deficient cells, and the groundwork for development of gene therapy approaches for A-T patients.
Results

Construction of HSV-1 amplicon vector carrying the FLAG-ATM
The HSV-1 amplicon vector carrying the full-length cDNA encoding NH 2 -terminal FLAG-tagged wild-type ATM is shown in Figure 1 . The basic amplicon HGCX has been previously described 28 and it contains: (i) HSV-1 ori s and pac; (ii) a reporter cassette consisting of EGFP under control of the HSV-1 immediate-early promoter, IE4/5; and (iii) a polycloning site downstream of the CMV promoter. The FLAG-ATM (9 kb) was inserted into the HGCX amplicon under control of the CMV promoter (designated pHGC-ATM). To generate the catalytically inactive ATM, the PI-3-kinase-related domain of ATM was mutated within the amplicon pHGC-ATM, as previously described, 11 and designated as pHGCATMkd. The molecular cloning of the complete ATM cDNA presented some technical difficulties because of inherent instability of this sequence; therefore, restriction enzyme mapping and sequencing were used to confirm that there were no deletions or rearrangements in the ATM insert. The efficiency of gene delivery was tested in different cell types in culture, measured as the percentage of EGFP + cells at 48 h postinfection by FACS analysis. The transduction efficiency at an MOI of 2 was 50-80% for the 293T/17 cells, and 30-50 and 10-30%, respectively, for the SV40-transformed human fibroblast lines from an A-T heterozygote (GM0637) and a patient with A-T (GM9607).
FLAG-ATM protein expression
Expression of the FLAG-ATM protein was first analyzed in 293T/17 cells by immunoprecipitation and Western blot analysis. 293T/17 cells were infected with the HGC-ATM amplicon vector and 48 h postinfection, the FLAG-ATM was immunoprecipitated using the anti-FLAG M2 antibody and Western blot analysis was performed with the ATM 2C1 antibody. Following this procedure, the ATM protein was detected only in the 293T/17 cells infected with the HGC-ATM amplicon vector ( Figure 2 ). Controls included uninfected 293T/17 cells and 293T/17 cells infected with the basic HGCX amplicon vector (data not shown). The amount of FLAG-ATM protein decreased several days postinfection because of loss of amplicon DNA during cell division and degradation of FLAG-ATM.
Localization of FLAG-ATM by immunofluorescence
Endogenous ATM is present predominantly within the nucleus of cultured cells, with a small fraction present in the cytoplasm. 29, 30 Immunostaining using anti-ATM (3E8) and anti-FLAG (FLAG M2) antibodies was used to localize the FLAG-ATM protein produced 48 h postinfection with the HGC-ATM amplicon vector. The results (Figure 3 ) indicate that the vector-expressed FLAG-ATM was also localized in the nucleus. In normal infected cells (293T/17) (Figure 3a-c), marked by the EGFP signal (Figure 3a) , the DAPI nuclear staining colocalized with the anti-FLAG immunostaining ( Figure  3c ). The A-T GM9607 cells harbor two mutations (5320del7, 8307G4A) in the ATM gene that causes a frameshift and premature termination. 31 Since truncated versions of the ATM protein are unstable, 32 no inmunoprotein was detected in the EGFP -cells with the anti- Figure 1 Cloning of the human ATM FLAG-tagged cDNA into the HGCX amplicon under control of the CMV promoter. This amplicon, designated pHGC-ATM, also bears an expression cassette for the EGFP under an immediate early (IE) HSV-1 promoter. The full-length cDNA encoding NH 2 -terminal FLAG-tagged wild-type ATM (B9 kb) was excised from pcDNA-FLAG-ATM wt and subcloned into the NotI/XhoI site of pHGCX. In vitro kinase assay ATM phosphorylates p53 directly on Ser-15 in response to IR. 11, 12 In vitro kinase assay of vector-derived FLAG-ATM from A-T GM9607 cells was carried out against recombinant glutathione S-transferase (GST)-conjugated p53 containing the first 101 amino acids of p53 (GSTp53 ) and a p53 mutant bearing a double (S15A, S37A) Ser-Ala amino acid substitution (Figure 4) . At 48 h after infection with HGC-ATM (wild type, wt), HGC-ATMkd, or control HGCX amplicon vectors, the FLAG-ATM protein was immunoprecipitated with an antibody to FLAG (Figure 4 , upper panel) and kinase activity was assayed. Equivalent amounts of the different FLAG-ATM proteins (wt and kd version) were immunoprecipitated and incubated with [g-32 P]adenosine triphosphate (ATP) and GST-p53 1-101 wild-type or mutant GSTp53 1-101 (S15A, S37A) peptides and then proteins resolved by SDS-PAGE and exposed to film (Figure 4 , middle panel). The use of an antibody to GST (Figure 4 , lower panel) demonstrates that the lanes were equally loaded. Only the vector-derived FLAG-ATM (wt version) was able to phosphorylate wt p53.
Cell cycle analysis after IR
A-T cells fail to initiate both the G 1 -and G 2 -phase checkpoints shortly after irradiation, although at longer times (15-24 h) after irradiation A-T cells remain blocked in G 2 /M for prolonged periods of time. 9, 10 The extent of accumulation of A-T cells in G 2 /M was assessed postirradiation. SV40-transformed human fibroblast A-T heterozygote (GM0637) or A-T (GM9607) cells were infected with HGCX and HGC-ATM amplicon vectors ( Figure 5 ). Cells were irradiated (3 Gy) 48 h postinfection, then cellular DNA was stained with Hoechst 33342 dye 24 h later. The cell cycle phase in the EGFP+ population was determined by FACS analysis, thereby over-riding the different transduction efficiency of these cell types. In the A-T cells (GM9607) infected with HGC-ATM vector, the extent of accumulation in G 2 /M phase 
Discussion
These studies demonstrate that the HSV-1 amplicon vector can be used to deliver a full-length, functional ATM cDNA to A-T cells, thus correcting their phenotypic deficits. Vector-derived ATM expression was determined by immunocytochemical identification of the FLAGtagged ATM cDNA construct. This protein was found to have the expected molecular weight (370 kD) by immunoprecipitation and Western blots, and to be localized in the cell nucleus, as is the normal ATM protein, by immunocytochemistry. Functional assays included the ability of the vector-derived FLAG-ATM to phosphorylate p53 in vitro at the correct position and to recover the ability to undergo cell cycle arrest in the G 2 /M phase after irradiation. This is the first demonstration of vector-mediated delivery of the large (9 kb) A-T cDNA to mammalian cells and paves the way for analyses of ATM functions and possible 'gene replacement' strategies for therapeutic purposes.
Our results in the analysis of the cell cycle are consistent with the literature, in general, in demonstrating an increase in the accumulation of A-T cells in G 2 /M after IR in A-T cell lines. However, our results differ from those presented by Zhang et al 21, 33 in that we observed a reduced ratio G 2 ÀM/G 0 ÀG 1 in response to radiation in A-T cells compared to normal cells. This is likely because of the use of SV40T for immortalization of A-T cells, as this protein has been reported to alter the cellular response to IR, making them more like normal cells. 34 HSV-1 amplicon vectors consist of a concatenate of amplicon DNA packaged into an HSV-1 virion. 35 In mammalian cells, in the presence of HSV helper functions, ori supports replication of amplicon DNA, as a rolling circle in the host cell nucleus. DNA concatemers are packaged into virion capsids by filling of empty capsids to the B150 kb capacity with cleavage at the extending pac signal. 25 Thus, within the virion, the amplicon vector genome is B150 kb long and would consist in the case of the HCG-ATM amplicon vector of 10 copies of the FLAG-ATM cDNA for each transducing unit. 25 This vector contains no viral coding sequences, but infected cells are exposed to proteins in the virion envelope, tegument and capsid, which can transitorily change their metabolic state, until they are degraded. 36 For example, there are two protein kinases in the tegument, UL13 and US3. 37 However, studies indicate no toxic effects of this vector per se when packaged in the helper virus-free state, although components of the cell lysate in the stocks can prove toxic to some cells when low titer vector stocks are used. Most cells are highly infectable with HSV-1 vectors, but in cases where a given cell type in culture is not, they HSV-1 amplicon-mediated expression of ATM cDNA ML Cortés et al can be transduced to express one of the HSV-1 receptor proteins, for example, HveA. 38, 39 Although the HSV-1 amplicon vector generated here can provide transgene expression for months in nondividing cells and for two to three generations in dividing cells, 25, 26, 40 ultimately, for therapeutic purposes it will be necessary to have a vector that provides stable transgene delivery in vivo. A number of vectors based on animal viruses have proven efficient at entering host cells and expressing genes in them, including those based on retrovirus, adenovirus, AAV, and HSV-1. Retrovirus, and derivative lentivirus vectors, can integrate transgenes into the genome of a variety of dividing and nondividing cell types, 41, 42 but are limited by their relatively small transgene capacity (B8 kb) and random integration. Adenovirus vectors have a larger transgene capacity, 30 kb in the 'gutless' version, 43 but have no mode of stable retention in the host cell nucleus. AAV vectors have a small transgene capacity (4.5 kb), and stably integrate into the genome of dividing and nondividing human cells, preferentially into the AAVS1 site of human chromosome 19 in the presence of the AAV Rep proteins. 44 Recent studies from our group and collaborators demonstrate that by flanking the transgene in amplicon vectors with the ITR elements and a Rep expression cassette from AAV, site-specific integration of the transgene at the AAVS1 chromosomal site can be achieved in about 10-30% of transduced human cells, 45, 46 as predicted from studies of AAV. 44, 47 We have now generated transgenic mice bearing the human AAVS1 locus, 48 which can be crossed to A-T heterozygous mice to create ATM K-O mice with AAVS1 sites, as a model of the human genome.
These studies demonstrate development of an efficient vector system for delivery of the ATM cDNA to A-Tdeficient human cells in culture with recovery of cell functions. A-T is a complex disease involving multiple tissue deficiencies. The development of a vector system for delivery of the ATM cDNA to cells, in culture and in vivo, will help in the elucidation of the functions of the normal protein in different cell types, and enhance the potential for correction of neurological and immunological, as well as other abnormalities in A-T by gene therapy.
Materials and methods
Cell culture
Simian virus 40-transformed human fibroblast lines from a healthy A-T heterozygote (GM0637) and a patient with A-T (GM9607) were obtained from the Coriell Cell Repositories. 293T/17 cells 49 were provided by Dr. David Baltimore (Massachusetts Institute of Technology, Cambridge, MA, USA), and African green monkey kidney Vero 2-2 cells 50 were provided by Dr Rozanne SandriGoldin (University of California, Irvine, USA). GM0637 and GM9607 cells were grown in Eagle's minimum essential medium (EMEM); 293T/17 and Vero 2-2 were grown in Dulbecco's modified Eagle's medium (DMEM). All media were supplemented with 10% fetal bovine serum (Sigma), 100 U penicillin and 0.1 mg of streptomycin (Sigma) per ml. Cells were grown at 371C and 5% CO 2 in a humidified atmosphere.
Construction of HSV amplicon vectors
The full-length cDNA encoding NH 2 -terminal FLAGtagged wild-type ATM (B9 kb) was excised from pcDNA-FLAG-ATMwt, 11 and subcloned into the NotI/ XhoI site of pHGCX, which also contains an expression cassette for enhanced green fluorescence protein (EGFP). 28 The cDNA was originally obtained from Dr Yossi Shiloh. 20 To generate catalytically inactive ATM, the PI-3-kinase-related domain of ATM was mutated within the amplicon, as previously described. 11 The control vector bears the EGFP transgene alone in the same amplicon backbone. The integrity of the amplicon constructs was evaluated by restriction analysis and sequencing.
Packaging of amplicon DNA into HSV-1 virions and titration of vector stocks
Helper virus-free packaging of HSV-1 amplicons into HSV-1 virions was performed as described previously. 28 Briefly, Vero 2-2 cells were cotransfected with 0.8 mg amplicon DNA, 2 mg fHSVDpac27 0+, and 0.2 mg pEB-HICP27 using LipofectAMINE (Gibco BRL, Rockville, MD, USA). After 3 days, transfected cells were scraped into medium, and the suspension was frozen and thawed once, sonicated, and centrifugated at 1400 g for 10 min to collect cell debris. The supernatant was used as vector stock. To determine vector titers (transducing units per milliliter; TU/ml), 293T/17 cells were infected with serial dilutions of vector and EGFP + cells were counted using a fluorescence microscope 24 h later.
Immunoprecipitation and western blotting
293T/17 cells were infected at an MOI of 2 with the HGC-ATM vector. At 48 h after infection, cells were harvested by trypsinization and centrifugation, and washed twice in Ca 2+ /Mg 2+ -free PBS. Pellets were resuspended in 2 x pellet volume with lysis buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM sodium ortho-vanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1 Â protease inhibitor cocktail (Boehringer-Mannhein, Indianapolis, ID, USA). Lysates were incubated on ice for 30 min, centrifugated at 17,000 g for 30 min and kept at 41C throughout. The protein concentrations were determined using the DC protein assay (Bio-Rad). The supernatants were precleared by incubation with protein A/G-agarose beads for 1 h. Following centrifugation, the supernatant was incubated with 4 ml of FLAG M2 antibody (Sigma) overnight. Then, 50 ml of protein A/G-agarose beads were added and incubated for 2 h. Beads were collected by centrifugation, washed two times with lysis buffer and once with PBS, and then resuspended in 20 ml 1 Â sample buffer. Samples were electrophoresed on 6% SDSpolyacrylamide gels according to the method of Laemmli. 51 After staining, the membranes were blocked in 10% nonfat dry milk powder in TBST (150 mM NaCl, 50 mM Tris, pH 7.9, 0.05% Tween). The blots were probed with ATM antibody, 2C1 (Genetex, San Antonio, TX, USA), diluted 1:500 in 2% milk in TBST and immunoreactive proteins were visualized with horseradish-peroxidaseconjugated secondary antibodies and the Supersignal s West Pico Chemiluminescent Substrate (Pierce, Rockford, Il, USA).
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In vitro kinase assays
In vitro kinase assays were performed as described previously. 11 Briefly, cell extracts were prepared from GM9607 fibroblasts infected with either FLAG ATMwt or ATMkd in lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Tween 20, 0.5% Nonidet P-40, 1 mM NaF, 1 mM PMSF and 1 Â protease inhibitor mixture from Roche Molecular Biochemicals). Cleared supernatants were immunoprecipitated with anti-FLAG M2 antibody immobilized on beads (Sigma). The beads were washed two times in the same lysis buffer, two times in the lysis buffer containing 0.5 M LiCl, and two times in kinase buffer (20 mM HEPES, pH 7.5, 50 mM NaCl, 10 mM MgCl 2 , 10 mM MnCl 2 , and 1 mM dithiothreitol). Finally, the immunoprecipitation was resuspended in 50 ml kinase buffer containing 5 mM ATP including 10 mCi [g 32 P] ATP and 1 mg of GST fusion substrate. Reactions were allowed to continue for 30 min at 301C and stopped by the addition of SDS-polyacrylamide loading buffer. Proteins were resolved by 4-12% SDS-polyacrylamide gel electrophoresis (Invitrogen) and transferred to nitrocellulose. Immunoprecipitation of FLAG-ATM was confirmed by Western blot analysis using FLAG M5 antibody (Sigma).
Immunocytochemistry
Cells grown on glass coverslips were infected with the HGCX and the HGC-ATM vectors at an MOI of 2. At 48 h after infection, cells were fixed with 4% paraformaldehyde in PBS for 20 min. After thorough rinsing with PBS, cells were incubated with 0.1% NP-40 in PBS for 20 min followed by blocking solution, 20% horse serum in PBS, for 1 h. Cells were incubated with FLAG M2 (1:600) or 3E8 (ATM monoclonal antibody, kindly provided by Dr Eva Lee at the University of Texas Health Science Center) dilution 1:2 for 1 h, then, with secondary antibody biotinylated anti-mouse IgG (1 h, 1: 500 dilution in PBS plus 2% BSA), and streptavidin-conjugated Alexa fluor 594 (Molecular Probes, Eugene, OR, USA, 1: 750 in PBS). Before mounting, cellular DNA was stained with DAPI (Molecular Probes, Eugene, OR, USA, 0.5 mg/ml) for 5 min. Coverslips were mounted onto slides using Dako s Fluorescent Medium (Dako, CA, USA). Cells were examined on an Olympus BX60 microscope, imaged using a Sony CCD color camera and analyzed with the Image-Pro Plus software.
Cell cycle assays
GM0637 and GM9607 cells were plated at a density of 10 5 cells per 60 mm dish. After 24 h, cells were infected with HGCX or HGC-ATM vectors, respectively, at an MOI of 2. At 48 h after infection, cells were irradiated with 3 Gy (IR was delivered from a 137 Cs source at 5.37 Gy/min.) Control cultures were exposed in an identical manner to their experimental counterparts. Cell cycle was assessed by staining with DNA dye Hoechst 33342 (Molecular Probes, Eugene, OR, USA) 24 h after IR. Cells were washed twice in PBS and fixed in 1% paraformaldehyde. Cells were then analyzed by flow cytometry for cell cycle and EGFP expression using a FACSVantage cell sorter (Becton Dickinson, San Jose, CA, USA) equipped with argon and UV laser lines. EGFP emission was detected on a logarithmic scale using a 525/30 bandpass filter, and UV emission was detected on a linear scale using a 424/ 44 bandpass filter.
Statistical analysis
Experiments were repeated three times and the data were calculated as the mean7s.d. A repeated measures ANOVA was used to assess statistical significance.
